Autor: |
Peter Bramlage, Sascha R Tittel, Gesine van Mark, Reinhard Welp, Jörg Gloyer, Stefan Sziegoleit, Ralf Barion, Peter M Jehle, Dieter Erath, Stefanie Lanzinger |
Jazyk: |
angličtina |
Rok vydání: |
2021 |
Předmět: |
|
Zdroj: |
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021) |
Druh dokumentu: |
article |
ISSN: |
2052-4897 |
DOI: |
10.1136/bmjdrc-2021-002215 |
Popis: |
Introduction The aims of this study were to characterize insulin-treated individuals aged ≥75 years with type 2 diabetes using basal insulin analogs (BIA) or regular insulins (human insulin (HI)/neutral protamine Hagedorn (NPH)) and to compare the benefits and risks.Research design and methods The analysis was based on data from the DPV (Diabetes-Patienten-Verlaufsdokumentation) and DIVE (DIabetes Versorgungs-Evaluation) registries. To balance for confounders, propensity score matching for age, sex, diabetes duration, body mass index and hemoglobin A1c (HbA1c) as covariates was performed.Results Among 167 300 patients aged ≥75 years with type 2 diabetes (mean age, 80.3 years), 9601 subjects used insulin regimens with basal insulin (HI/NPH or BIA). Of these 8022 propensity score-matched subjects were identified. The mean diabetes duration was ~12 years and half of the patients were male. At the time of switch, patients provided with BIA experienced more dyslipidemia (89.3% vs 85.9%; p=0.002) and took a greater number of medications (4.3 vs 3.7; p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|